A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
This paper presents a detailed systems model of Parkinson's disease (PD), developed utilizing a pragmatic application of biochemical systems theory (BST) intended to assist experimentalists in the study of system behavior. This approach utilizes relative values as a reasonable initial estimate for BST and provides a theoretical means of applying numerical solutions to qualitative and semi-quantitative understandings of cellular pathways and mechanisms. The approach allows for the simulation of human disease through its ability to organize and integrate existing information about metabolic pathways without having a full quantitative description of those pathways, so that hypotheses about individual processes may be tested in a systems environment. Incorporating this method, the PD model describes alpha-synuclein aggregation as mediated by dopamine metabolism, the ubiquitin-proteasome system, and lysosomal degradation, allowing for the examination of dynamic pathway interactions and the evaluation of possible toxic mechanisms in the aggregation process. Four system perturbations: elevated alpha-synuclein aggregation, impaired dopamine packaging, increased neurotoxins, and alpha-synuclein overexpression, were analyzed for correlation to qualitative PD system hypotheses present in the literature, with the model demonstrating a high level of agreement with these hypotheses. Additionally, various PD treatment methods, including levadopa and monoamine oxidase inhibition (MAOI) therapy, were applied to the disease models to examine their effects on the system. Future additions and refinements to the model may further the understanding of the emergent behaviors of the disease, helping in the identification of system sensitivities and possible therapeutic targets.
Sass
Matthew B
MB
Department of Chemistry, Integrated Science Center, The College of William and Mary, Williamsburg, VA 23187, USA.
Lorenz
Alyson N
AN
Green
Robert L
RL
Coleman
Randolph A
RA
D000682:Amyloid / Q000378:metabolism; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003198:Computer Simulation; D004298:Dopamine / Q000031:analogs & derivatives / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D016631:Lewy Bodies / Q000187:drug effects / Q000502:physiology; D008247:Lysosomes / Q000502:physiology; D008959:Models, Neurological; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009498:Neurotoxins / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D013598:Systems Theory; D025801:Ubiquitin / Q000378:metabolism; D051844:alpha-Synuclein / Q000378:metabolism*
D000682:Amyloid; D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D009498:Neurotoxins; D017382:Reactive Oxygen Species; D025801:Ubiquitin; D051844:alpha-Synuclein; D007980:Levodopa; C104705:dopamine quinone; D046988:Proteasome Endopeptidase Complex; D004298:Dopamine